Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.41 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908715 | 0.92 | HTR2C (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL14018046 | 0.91 | HTR2C (0.40) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL30827039 | 0.86 | LMNA (0.52) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL588937 | 0.81 | ADORA3 (0.53) | ADORA3ADORA1ADORA2A | |
| SCHEMBL9692356 | 0.81 | ABCB1 (0.48) | ADCY5ABCB1 | |
| SCHEMBL242510 | 0.80 | ADORA1 (0.42) | HTR2CHTR2BADORA3ADORA1TMIGD3 | |
| SCHEMBL1401993 | 0.80 | ADORA1 (0.42) | HTR2CHTR2BADORA3ADORA1TMIGD3 | |
| SCHEMBL12060833 | 0.80 | LMNA (0.39) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL12050236 | 0.78 | LMNA (0.40) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL27087639 | 0.77 | LMNA (0.56) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2018388-B9 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2018388-B1 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885TP53 969/4885ALDH1A1 166/4885 |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | LMNA 2569/4885TP53 3227/4885ALDH1A1 333/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885TP53 969/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.